CLINICAL AND PRACTICAL SIGNIFICANCE OF HEMOPHILIA
DOI:
https://doi.org/10.55640/Keywords:
Hemophilia, Hemophilia A, Hemophilia B, Hemophilia C, hematoma, hemarthrosis, antifibrinolytic drugs, hereditary disease, bleeding, chromosome,Abstract
This scientific article discusses the types of hemophilia, their pathogenesis, clinical manifestations, and treatment methods. Hemophilia is a hereditary disorder of the blood coagulation system that occurs as a result of a deficiency of certain clotting factors in the body. Hemophilia A is characterized by a deficiency of factor VIII, hemophilia B by a deficiency of factor IX, and hemophilia C by a deficiency of factor XI. In this disease, bleeding tends to last for a long time, and hematomas under the skin and in muscles, as well as bleeding into joints (hemarthrosis), occur frequently. Treatment of patients focuses on replacing the missing clotting factors, using antifibrinolytic drugs, and treating hematomas through physiotherapy or surgical methods. Special attention is also given to the concept of hematoma. A hematoma is an accumulation of blood that escapes from a vessel and collects within tissues, and it is one of the most common complications of hemophilia. The article highlights the relationship between hemophilia and hematoma, emphasizing the importance of early diagnosis, prevention, and appropriate treatment.
Downloads
References
1.World Federation of Hemophilia (WFH). (2023). Guidelines for the Management of Hemophilia (3rd ed.). Montreal: WFH Publications.
2.Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et al. (2020). Guidelines for the management of hemophilia. Haemophilia, 26(S6), 1–158.
3.Bolton-Maggs, P. H. B., & Pasi, K. J. (2003). Haemophilias A and B. The Lancet, 361(9371), 1801–1809.
4.Hoffman, R., Benz, E. J., Silberstein, L. E., Heslop, H., & Weitz, J. (2018). Hematology: Basic Principles and Practice (7th ed.). Philadelphia: Elsevier.
5.Berntorp, E., & Shapiro, A. D. (2012). Modern haemophilia care. The Lancet, 379(9824), 1447–1456.
6.Peyvandi, F., Garagiola, I., & Young, G. (2016). The past and future of haemophilia: Diagnosis, treatments, and its complications. The Lancet, 388(10040), 187–197.
7.Mannucci, P. M., & Tuddenham, E. G. D. (2001). The hemophilias — from royal genes to gene therapy. The New England Journal of Medicine, 344(23), 1773–1779.
8.White, G. C., Rosendaal, F., Aledort, L. M., et al. (2001). Definitions in hemophilia: Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX. Thrombosis and Haemostasis, 85(3), 560.
9.Srivastava, A., & Poon, M. C. (2019). Prophylaxis in haemophilia: Evolution and clinical impact. Haemophilia, 25(S1), 6–12.
10.Karimi, M., & Peyvandi, F. (2015). Hemophilia and other congenital bleeding disorders in developing countries. Seminars in Thrombosis and Hemostasis, 41(5), 504–510.
11.Goudemand, J., & Rothschild, C. (2010). Replacement therapy in hemophilia: Past, present, and future. Blood Reviews, 24(6), 255–261.
12.World Health Organization. (2022). Hereditary bleeding disorders: Diagnosis and management guidelines. Geneva: WHO Press.
13.Uzbekistan Ministry of Health. (2021). Gemofiliya kasalligini tashxislash va davolash bo‘yicha klinik qo‘llanma. Toshkent: Sog‘liqni saqlash vazirligi nashriyoti.
14.Akramova, X. X. (2024). Gemofiliya kasalligining klinik xususiyatlari va davolash yondashuvlari. Qo‘qon Universiteti Ilmiy jurnali, 2(4), 45–52.
15.Hasanboyev, Z., & Soyibjonova, M. (2025). Gemofiliya va uning asoratlarini oldini olishda profilaktikaning ahamiyati. Andijon Tibbiyot Instituti Talabalar To‘plami, 3(1), 88–93.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India